Brown Advisory Inc. boosted its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 75.2% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 328,740 shares of the company’s stock after purchasing an additional 141,076 shares during the period. Brown Advisory Inc.’s holdings in Global Blood Therapeutics were worth $13,493,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Lindbrook Capital LLC acquired a new position in shares of Global Blood Therapeutics in the fourth quarter worth about $55,000. Bank of Montreal Can raised its position in shares of Global Blood Therapeutics by 61.9% in the fourth quarter. Bank of Montreal Can now owns 1,582 shares of the company’s stock worth $65,000 after acquiring an additional 605 shares during the period. Strs Ohio acquired a new position in shares of Global Blood Therapeutics in the fourth quarter worth about $65,000. Focused Wealth Management Inc acquired a new position in shares of Global Blood Therapeutics in the third quarter worth about $104,000. Finally, PNC Financial Services Group Inc. raised its position in shares of Global Blood Therapeutics by 740.3% in the third quarter. PNC Financial Services Group Inc. now owns 4,353 shares of the company’s stock worth $165,000 after acquiring an additional 3,835 shares during the period.

A number of brokerages have weighed in on GBT. Wedbush upped their price objective on shares of Global Blood Therapeutics from $91.00 to $95.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 5th. Zacks Investment Research downgraded shares of Global Blood Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, March 4th. Morgan Stanley upped their price target on shares of Global Blood Therapeutics from $55.00 to $57.00 and gave the stock an “equal weight” rating in a research report on Monday, March 4th. JPMorgan Chase & Co. restated a “buy” rating and set a $75.00 price target on shares of Global Blood Therapeutics in a research report on Thursday, February 28th. Finally, Guggenheim assumed coverage on shares of Global Blood Therapeutics in a research report on Friday, February 22nd. They set a “buy” rating and a $75.00 price target for the company. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Global Blood Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $85.79.

Shares of NASDAQ GBT opened at $52.53 on Friday. Global Blood Therapeutics Inc has a 12-month low of $30.15 and a 12-month high of $55.20. The stock has a market cap of $3.01 billion, a P/E ratio of -15.40 and a beta of 2.13.

Global Blood Therapeutics (NASDAQ:GBT) last announced its quarterly earnings data on Wednesday, February 27th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.04). During the same quarter in the prior year, the firm earned ($0.95) EPS. As a group, equities analysts expect that Global Blood Therapeutics Inc will post -3.89 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Brown Advisory Inc. Boosts Position in Global Blood Therapeutics Inc (GBT)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.thecerbatgem.com/2019/03/15/brown-advisory-inc-boosts-position-in-global-blood-therapeutics-inc-gbt.html.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities. It is developing its lead product candidate, voxelotor, an oral, once-daily therapy for sickle cell disease (SCD). The company is evaluating voxelotor in SCD in a Phase III clinical trial in adult and adolescent patients with SCD.

Read More: What causes a recession?

Want to see what other hedge funds are holding GBT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Global Blood Therapeutics Inc (NASDAQ:GBT).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.